Skip to main content
. 2022 May 18;10:884467. doi: 10.3389/fcell.2022.884467

FIGURE 5.

FIGURE 5

Overview of Wnt targeting drugs. Several classes of biological and small molecule Wnt-targeting drugs have been developed and studied for anti-cancer activity. The most important include monoclonal antibodies targeting secreted Wnt ligands (Ipafricet) or their receptors (Vantictumab), tankyrase inhibitors (XAV939, JW55, G007-LK, IWR1), disheveled inhibitors (3289–8625, NSC-668036), PORCN inhibitors (LGK974, IWP2), and inhibitors of the β-catenin:TCF/LEF transcriptional complex (iCRT3. iCRT5, iCRT14, GGP049090, PFK115-584).